|  | 
| Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study. | 
|  | 
|  | 
| Consulting or Advisory Role - Genomic Health; IntegraConnect | 
| Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Dendreon; Janssen Oncology; Sanofi | 
|  | 
|  | 
| Honoraria - Dendreon; Janssen Oncology; Sanofi | 
| Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi | 
| Speakers' Bureau - Dendreon; Sanofi | 
| Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst) | 
| Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst) | 
| Travel, Accommodations, Expenses - Dendreon; Janssen Biotech; Medivation; Sanofi | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Swan Valley Medical | 
| Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas | 
| Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas | 
| Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Medivation | 
| Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Janssen (Inst); Medivation/Astellas (Inst); Spectrum Pharmaceuticals | 
| Travel, Accommodations, Expenses - Astellas Pharma; Bayer; dendreon; Janssen; Medivation/Astellas; Spectrum Pharmaceuticals | 
|  | 
|  | 
| Employment - Astellas Pharma | 
|  | 
|  | 
| Consulting or Advisory Role - Astellas Pharma | 
|  | 
|  | 
| Research Funding - Astellas Medivation (Inst); BHR Pharma (Inst); Churchill Pharmaceuticals (Inst); Dendreon (Inst); Eleven Biotherapeutics (Inst); Ferring (Inst); Janssen Oncology (Inst); Myovant Sciences (Inst); pfizer (Inst); Siemens (Inst) | 
|  | 
|  | 
| Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Novartis; Pfizer | 
| Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst) | 
|  | 
|  | 
| Employment - QuintilesIMS | 
| Travel, Accommodations, Expenses - Astellas Pharma | 
|  | 
|  | 
| Employment - Astellas Pharma | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Egenix; Exelixis (I) | 
| Research Funding - Advantagene (Inst); Dendreon (Inst); Medivation (Inst) | 
| Other Relationship - American Urological Association | 
|  | 
|  | 
| Employment - Astellas Pharma | 
|  | 
|  | 
| Employment - QuintilesIMS | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Employment - QuintilesIMS | 
|  | 
|  | 
| Consulting or Advisory Role - Astellas Pharma; Dendreon | 
| Research Funding - Astellas Pharma (Inst); Medivation (Inst) |